Conceptus, Inc.

• A Strategic Healthcare Deal With an Expensive Price Tag

  By Anh HOANG - May 8, 2013 | Tickers: BAYRY.PK, CPTS, HOLX

  Recently, Bayer AG (NASDAQOTH: BAYRY.PK) has announced that it will acquire Conceptus (NASDAQ: CPTS) at an average of $31 per share in cash, with a total transaction value of $1.1 billion. The offering price represented a 20% premium to its trading level of $25.90 on April 26. Conceptus’ shareholders must be quite happy, as Conceptus’ share price has experienced a sweet gain of as much as 47.7 more »

• Avoid this Diagnostics Company

  By Meena Krishnamsetty - May 1, 2012 | Tickers: CPTS, GPRO, HOLX, NVS, QGEN

  This week Hologic (NASDAQ: HOLX) announced it would acquire Gen-Probe (NASDAQ: GPRO) for $3.7 billion or $82.75/share, a 20% premium based on last Friday’s close, representing ~6.0x CY 2012 revenue and ~23.0x CY 2012EBITDA, pre-synergies. The transaction financing will be all-cash and is expected to close later this year. The companies are projecting $75 million in synergies over three years, making the deal theoretically more »